Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in HER-2 negative advanced breast cancer with chest wall metastasis
NCT02878057Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Progression-Free Survival at 6 months and Overall Survival at 55 months. Started May 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02878057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878057.